A Randomised, Double-blind, Parallel-group, Explorative Study of the Safety, Tolerability, and Pharmacokinetics of Daily Dosing Compared to Weekly Dosing of Zicronapine in Patients With Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2016
At a glance
- Drugs Zicronapine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 28 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 28 Feb 2012 Actual patient number is 42 according to ClinicalTrials.gov.
- 28 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.